PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
about
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasRhabdomyosarcoma: Advances in Molecular and Cellular BiologyCell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcomaAdvances in sarcoma diagnostics and treatmentMicroenvironmental Targets in SarcomaDNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsiesRecurrent fusion RNA DUS4L-BCAP29 in non-cancer human tissues and cells.Intergenically Spliced Chimeric RNAs in Cancer.Lineage of origin in rhabdomyosarcoma informs pharmacological responseAberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profilingMyogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP miceToward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7.Rhabdomyosarcoma in adolescent and young adult patients: current perspectives.Pediatric Rhabdomyosarcoma.Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.What is new in the biology and treatment of pediatric rhabdomyosarcoma?Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.Rhabdomyosarcoma: current challenges and their implications for developing therapies.Notch signaling in pediatric soft tissue sarcomasA novel algorithm for simplification of complex gene classifiers in cancer.Human growth is associated with distinct patterns of gene expression in evolutionarily conserved networks.Investigation of osteosarcoma genomics and its impact on targeted therapy: an international collaboration to conquer human osteosarcoma.Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology GroupComprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupPAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.Orbital rhabdomyosarcomas: A review.Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themesManagement and outcome of 239 adolescent and adult rhabdomyosarcoma patients.Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo.Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcomaA panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
P2860
Q26782842-1AFDAE01-9AF0-49D9-AE54-77BBD9D1CA5CQ26784207-944E8459-512B-4F02-B7CB-9FF206D1B4DBQ27317150-A46CAA0F-AA32-456D-98C4-20FF540E0B88Q28069695-2CC5DE8A-E9B7-41C1-87CA-DED10070B32CQ28081400-5BC7A1BA-39DE-4130-84E6-89A1AC2ED307Q28282708-D1DFA6BB-C61F-4AB2-B421-4E2A55F9DFE2Q30252613-E8683051-1D67-4E62-8A1C-105AEE2B1476Q30274742-FD4AB771-D10B-43CF-9338-80CD39A91435Q30411722-5C859D1F-CCBA-47EA-86FC-09508F401A8CQ30563970-25E7C7B8-743B-4E8C-B5BD-44F8942A63C6Q33567593-DDFB0A64-9611-4D11-A08A-E496A713FFAEQ33567866-F0AF7C27-7737-454E-A365-766C9A7F5663Q33601298-14932EC6-34E0-4A60-8BA0-23F3D7BFCF17Q33794219-8CD0FC3F-0530-4A20-AD91-30AA85A9C1EAQ33800135-5CF83360-2028-4BAB-A6DF-74116A0C8367Q33842070-9076AB26-6FA3-4A61-856B-54C651510581Q33860694-D85975D7-1122-43F4-9CBC-BD0CBCD9CC22Q33895506-381FEF96-C492-439C-B868-974DEB32875CQ34340295-72BB85E2-69A6-4066-8E29-2A817410B1AEQ34400242-D8E7CDFA-2E9D-4A06-8722-7B1FC5810860Q34480012-D953D408-A98A-4418-8906-C1D8A83CF309Q34520679-3C09B501-577E-44AE-8ABB-80D8601356CEQ34938931-FC5DD892-3E53-4D5B-B94E-9EDFDBF348A7Q35020434-47803DDA-3D71-4BFC-AB77-042E36F4FC2BQ35602170-8661217F-ECBF-4076-BE1F-9B43460C56BEQ35667137-BCAF9927-C84A-4275-BDA7-0D85327DEE26Q35688154-86507D82-8B9D-4C30-B961-A527A4BABE0EQ35711420-594E010C-C8DD-4B0A-A27C-05C0558B471EQ36040768-240BAED1-F9A6-465B-8C61-D357ABFBA426Q36175120-EAB85BC0-C383-43FF-9CB1-17B5EABD342BQ36283044-838988E4-0F25-4712-B28E-44183B159BD3Q36460093-9016CA4A-8320-409A-BB2F-D2881D0D0529Q36903863-F114CA50-D760-4A88-9A37-EFF6704DA3E8Q37163456-0356544A-4A29-467B-9C72-D508C6732DEDQ37234080-EC30471F-C547-4A39-9B62-1F354DF90EEAQ37236280-A7C91B15-1FF2-498E-B952-5B83975CA924Q37281508-4EBDF220-B2AE-4FDE-94C5-9AB4C591709BQ37381276-8530378D-A7F9-46B4-8CE7-4DFD660322ABQ37688414-EE8519A7-28DE-4DB1-BB7C-B0D556BC6A01Q38105879-D487D4C8-E034-4123-8DC9-F1DDB29E366A
P2860
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@en
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@nl
type
label
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@en
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@nl
prefLabel
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@en
PAX3/FOXO1 fusion gene status ...... s current risk stratification.
@nl
P2093
P50
P356
P1476
PAX3/FOXO1 fusion gene status ...... es current risk stratification
@en
P2093
Dan Williamson
Fabien Petel
Gaëlle Pierron
Julia Chisholm
Khin Thway
Mauro Delorenzi
Odile Oberlin
Pratyaksha Wirapati
P304
P356
10.1200/JCO.2011.38.5591
P407
P577
2012-03-26T00:00:00Z